Boehringer plans to develop Nerio's inhibitors as standalone treatments and in combination with other cancer therapies being ...

Boehringer Ingelheim has joined forces with ... who is chief executive and co-founder of Brainomix, a spinout from the University of Oxford in the UK. "This will enable earlier access to ...